Ryoncil (remestemcel-L) has a list price of $194,000 per infusion, and the labeled course is eight infusions over four weeks. That puts a full course at about $1.55 million at list price before any hospital care. The drug is approved only for children with steroid-refractory acute graft versus host disease, and the list price is not the amount a family pays out of pocket.
Ryoncil Cost per Infusion and per Course
Ryoncil costs $194,000 per intravenous infusion at its wholesale acquisition cost (WAC), the list price Mesoblast set in its February 26, 2025 pricing announcement. Mesoblast charges the same $194,000 for every infusion, whatever the child’s body weight. Mesoblast has not published a single price for a full course, so the course total below is arithmetic on the per-infusion figure.
The same announcement gives the dosing schedule. Each infusion delivers 2 million mesenchymal stromal cells per kilogram of body weight. Infusions are given twice a week for four weeks in a row, which adds up to eight infusions.
| Item | Figure | Where it comes from |
|---|---|---|
| List price per infusion (WAC) | $194,000 | Mesoblast pricing announcement |
| Dose per infusion | 2 million cells per kg of body weight | Mesoblast pricing announcement |
| Schedule | Twice a week for 4 consecutive weeks | Mesoblast pricing announcement |
| Infusions per course | 8 | 2 per week x 4 weeks |
| Course total at list price | $1,552,000 | Medical Frontier’s calculation: 8 x $194,000 |
The $1,552,000 figure is Medical Frontier’s calculation, and Mesoblast did not publish it. It covers the drug at list price only. It leaves out the hospital stay, transplant-center care and every other cost of treatment, and it is not what any patient or insurer is known to pay.
The flat price has one practical effect. The dose rises with body weight, but the price does not. A 2-month-old and a teenager each carry the same $194,000 list price per infusion.
FDA Approval for Children With Steroid-Refractory Acute GVHD
The Food and Drug Administration (FDA) approved Ryoncil on December 18, 2024, for one group of patients. That group is pediatric patients 2 months of age and older, including adolescents and teenagers, with steroid-refractory acute graft versus host disease (SR-aGvHD). Ryoncil was the first mesenchymal stromal cell therapy the FDA approved, and the approval applies only in the United States.
Ryoncil is a hospital transplant-setting product, not something a knee clinic, wellness center or anti-aging practice sells. Adults are not an approved population today. Our guide to what Ryoncil is covers how it is dosed, what the approval trial showed and the side effects the FDA lists.
That distinction affects how you read stem cell marketing. Our FDA status guide explains what approval does and does not cover. Our overview of mesenchymal stem cells explains how the cell type in Ryoncil relates to products sold elsewhere.
Insurance Coverage for the Ryoncil Price
Mesoblast runs MyMesoblast, which it describes as a comprehensive patient services hub where Ryoncil is available for ordering.
Aetna Clinical Policy Bulletin 1077 covers Ryoncil only for pediatric SR-aGvHD. The bulletin treats every other indication as experimental, investigational or unproven.
Medical Frontier has no published figure for what any other insurer, Medicare or Medicaid pays for Ryoncil. Our guides on Medicare and Medicaid cover each program’s general stem cell rules. Before treatment starts, put these questions to your plan, using the framework in our insurance coverage guide:
- Does the plan cover Ryoncil for my child’s diagnosis?
- Does the plan require prior authorization before the first infusion?
- Which costs fall on us: the drug, the hospital stay, or both?
- Is the treating transplant center in the plan’s network?
- What is our out-of-pocket maximum for the year?
Clinic pricing for IV treatments is covered in our IV stem cell therapy cost guide.
First Full Year of Ryoncil Sales
Mesoblast launched Ryoncil in the United States in March 2025. Mesoblast’s report for fiscal year 2026, the year ended June 30, 2026, was filed in mid-October 2026. It showed Ryoncil net product sales of $115.2 million.
| Measure | Figure |
|---|---|
| Ryoncil net product sales, fiscal year 2026 | $115.2 million |
| Mesoblast total revenue, fiscal year 2026 | $120.3 million |
| Mesoblast total revenue, fiscal year 2025 | $17.2 million |
| Gross profit, fiscal year 2026 | About $104 million |
More than 50 treatment centers were onboarded by the end of the first launch year. They include most of the country’s highest-volume pediatric transplant institutions.
The approved group could grow. During fiscal year 2026, a Phase 3 registration trial in adults with SR-aGvHD began with the NIH-funded BMT CTN. The trial is enrolling at multiple U.S. sites. No readout date or filing timeline is published, and adults are not an approved population today.
Clinic Stem Cell Prices Compared With the Ryoncil Price
Ryoncil’s price tells you nothing about what a clinic will charge for a stem cell injection. Ryoncil is not approved for knee arthritis, back pain, wellness or anti-aging, and clinics offering injections for those uses are not selling Ryoncil.
The FDA approval covers one product, from one manufacturer, for one pediatric condition, and our FDA status guide lists what that leaves out.
| Feature | Ryoncil | Clinic stem cell injection |
|---|---|---|
| FDA status | Approved December 18, 2024 | Unapproved for knee, back, wellness or anti-aging use |
| Setting | Hospital transplant setting | Clinic |
| Published price | $194,000 per infusion (WAC) | Varies by clinic |
| Insurance | Aetna covers the approved pediatric use | See our insurance coverage guide |
The general reasons clinic prices vary are in our guide to why stem cell therapy is so expensive, and the cost hub collects every pricing guide we publish. Before you compare any clinic quote with the Ryoncil cost, read our stem cell injection cost guide.
Frequently asked questions
How much does Ryoncil cost?
Ryoncil has a list price of $194,000 per intravenous infusion, the wholesale acquisition cost Mesoblast announced on February 26, 2025. The labeled schedule is two infusions a week for four weeks, or eight infusions in total. By Medical Frontier's arithmetic, a full course comes to $1,552,000 at list price. That figure leaves out the hospital stay and other transplant-center care, and it is not what any patient or insurer is known to pay.
Is Ryoncil FDA approved?
Yes. The Food and Drug Administration (FDA) approved Ryoncil (remestemcel-L) on December 18, 2024. The approval covers patients 2 months of age and older, including adolescents and teenagers, who have steroid-refractory acute graft versus host disease. Ryoncil was the first mesenchymal stromal cell therapy the FDA approved, and the approval applies only in the United States. Our FDA status guide explains how approved products differ from clinic offerings.
Who manufactures Ryoncil?
Mesoblast manufactures Ryoncil. Mesoblast set the drug's list price, launched it in the United States in March 2025, and runs a patient services hub called MyMesoblast, where Ryoncil is available for ordering.
Does insurance cover Ryoncil?
Aetna covers Ryoncil only for children with steroid-refractory acute graft versus host disease and treats every other use as experimental, investigational or unproven. Medical Frontier has no published figure for what any other plan pays for Ryoncil. Ask your health plan directly, using the questions in our insurance coverage guide.
Is Ryoncil approved for adults or for knees?
No. Ryoncil's FDA approval covers only pediatric patients 2 months and older with steroid-refractory acute graft versus host disease. A Phase 3 trial in adults with the same condition is enrolling at multiple U.S. sites, but no readout date or filing timeline is published. Ryoncil is not approved for knee arthritis, back pain, wellness or anti-aging, and clinics offering stem cell injections for those uses are not selling Ryoncil. See our stem cell injection cost guide for clinic pricing.
Medical disclaimer. Medical Frontier is an independent educational resource. This page is for general information only and is not medical advice, diagnosis, or treatment, and does not create a doctor–patient relationship. Most regenerative therapies discussed here are not FDA-approved for the uses described and may be offered under limited exemptions or in clinical trials only. Always consult a licensed physician before making any treatment decision.